Alterity Therapeutics Limited

The momentum for this stock is not very good. Alterity Therapeutics Limited is not very popular among insiders. Tradey thinks it is not wise to invest in Alterity Therapeutics Limited.

News

Alterity Therapeutics Limited (NASDAQ:ATHE) Sees Significant Decrease in Short Interest

Ticker Report Alterity Therapeutics Limited (NASDAQ:ATHE - Get Free Report) was the target of a significant decrease in short interest in August. As of August 15th, there was short interest totalling 23,000...\n more…

Alterity Therapeutics Unveils Annual Financial Results

TipRanks Financial Blog Alterity Therapeutics Ltd. (AU:ATH) has released an update. Alterity Therapeutics Limited has released its Preliminary Final Report for the year ending 30 June 2024...\n more…

Alterity Therapeutics reports cash balance of A$12.6M as of June 30

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Appendix 4C Q4 FY24 Quarterly Cash Flow Report

Globe Newswire Highlights Positive interim data reported from ATH434-202 Phase 2 clinical trial showing improvement on the UMSARS Activities of Daily Living Scale and stable or improved neurological symptoms in...\n more…

Alterity Therapeutics to Present at MST Financial Webinar

Globe Newswire MELBOURNE, Australia and SAN FRANCISCO, July 24, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ( Alterity or the Company ), a biotechnology company dedicated to...\n more…

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Globe Newswire 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale 29% of Participants had Stable or Improved Neurological Symptoms Objective Biomarkers...\n more…